Chromogranin A measurement in metastatic well-differentiated gastroenteropancreatic neuroendocrine carcinoma: Screening for false positives and a prospective follow-up study

International Journal of Biological Markers

Volumn 26, Issue 2, 2011, Pages 94-101

  Vezzosi, Delphine ^a   Walter, Thomas ^b   Laplanche, Agnès ^a   Raoul, Jean Luc ^c   Dromain, Clarisse ^a   Ruszniewski, Philippe ^d   d'Herbomez, Michèle ^e   Guigay, Joël ^a   Mitry, Emmanuel ^f   Cadiot, Guillaume ^g   Leboulleux, Sophie ^a   Lombard Bohas, Catherine ^b   Borson Chazot, Françoise ^h   Ducreux, Michel ^a   Baudin, Eric ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d BEAUJON HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

^g SERVICE DE DERMATOLOGIE   (France)

^h Fédération d'Endocrinologie Groupement Hospitalier Est   (France)

Author keywords

Chromogranin a; False positives; Gastroenteropancreatic endocrine carcinoma; Prospective study

Indexed keywords

CHROMOGRANIN A; CREATININE; GASTRIN; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CANCER GROWTH; CANCER SCREENING; CONTROLLED STUDY; CREATININE CLEARANCE; CUSHING SYNDROME; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INTESTINE CANCER; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PRIMARY TUMOR; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; WELL DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA;

ADULT; AGED; CARCINOMA, NEUROENDOCRINE; CHROMOGRANIN A; FALSE POSITIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959316686     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8327     Document Type: Article

References (36)

1. O'Toole D, Grossman A, Gross D, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 2009; 90: 194-202.
2. Baudin E, Bidart JM, Bachelot A, et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 2001; 12 (Suppl 2): S79-82.
3. Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78: 1102-7.
4. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 1991; 70: 33-45.
5. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 1967-73.
6. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622-8.
7. Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13: 55-8.
8. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001; 12 (Suppl 2): S69-72.
9. Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian multicenter study. Endocr Relat Cancer 2007; 14: 473-82.
10. Leon A, Torta M, Dittadi R, et al. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study. Int J Biol Markers 2005; 20: 156-68.
11. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of shortterm treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004; 150: 299-303.
12. Syversen U, Mignon M, Bonfils S, Kristensen A, Waldum HL. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol 1993; 32: 161-5.
13. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37: 955-64.
14. Pieroni M, Corti A, Tota B, et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007; 28: 1117-27.
15. Nobels FR, de Herder WW, Kwekkeboom DJ, et al. Serum chromogranin A in the differential diagnosis of Cushing's syndrome. Eur J Endocrinol 1994; 131: 589-93.
16. Sciola V, Massironi S, Conte D, et al. Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 867-71.
17. Al-Shoumer KA, Vasanthy BA. Serum chromogranin A concentration in hyperthyroidism before and after medical treatment. J Clin Endocrinol Metab 2009; 94: 2321-4.
18. Berruti A, Dogliotti L, Mosca A, et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001; 12 (Suppl 2): S153-7.
19. Granberg D, Stridsberg M, Seensalu R, et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999; 84: 2712-7.
20. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999; 86: 858-65.
21. Abou-Saif A, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer 2003; 98: 249-61.
22. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60: 644-52.
23. Nikou GC, Marinou K, Thomakos P, et al. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with nonfunctioning pancreatic endocrine tumours. Pancreatology 2008; 8: 510-9.
24. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6: 820-7.
25. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798-803.
26. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76.
27. Welin S, Stridsberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009; 89: 302-7.
28. Solcia E, Klöppel G, and Sobin L. Histological typing of endocrine tumours. WHO international histological classification of tumours. Berlin: Springer, 2000.
29. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 2007; 451: 757-62.
30. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
31. Marie I, Moutot A, Tharrasse A, et al. Validity of proton pump inhibitors' prescriptions in a department of internal medicine. Rev Med Interne 2007; 28: 86-93.
32. Stridsberg M, Eriksson B, Fellstrom B, Kristiansson G, Tiensuu Janson E. Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Pept 2007; 139: 80-3.
33. Sundin A, Vullierme MP, Kaltsas G, Plockinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology 2009; 90: 167-83.
34. Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177: 337-41.
35. Verderio P, Dittadi R, Marubini E, et al. An Italian program of external quality control for chromogranin A (CgA) assay: performance evaluation of CgA determination. Clin Chem Lab Med 2007; 45: 1244-50.
36. Stivanello M, Berruti A, Torta M, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 2001; 12 (Suppl 2): S73-7.